title: β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
abstract: OBJECTIVE
  β1,6-N-acetylglucosaminyltransferase V (MGAT5), which is required for the biosynthesis of β1,6GlcNAc-branched N-linked glycans attached to cell surface and secreted glycoproteins, accounts for oncogenic growth signal transduction during the development and progression of various malignancies. Our present study aimed to evaluate the impact of MGAT5 expression on recurrence and survival of patients with clear-cell renal cell carcinoma (ccRCC) following surgery.
  
  
  METHODS
  We retrospectively enrolled 265 patients (196 in the training cohort and 69 in the validation cohort) with ccRCC undergoing nephrectomy at a single institution. Clinicopathologic features, overall survival (OS) and recurrence-free survival (RFS) were recorded. MGAT5 intensities were assessed by immunohistochemistry in specimens of patients. Kaplan-Meier method was applied to compare survival curves. Cox regression models were used to analyze the impact of prognostic factors on OS and RFS. Concordance index (C-index) was calculated to assess predictive accuracy.
  
  
  RESULTS
  In both cohorts, MGAT5 expression positively correlated with metastatic and advanced TNM stage. High MGAT5 expression indicated poor survival (P < 0.001 in training set and P < 0.001 in validation set) and early recurrence (P < 0.001 in training set and P = 0.004 in validation set) of patients with ccRCC. After multivariate Cox regression analysis, MGAT5 expression was identified as an independent adverse prognostic factor for survival and recurrence. The predictive accuracy of TNM, UISS and SSIGN prognostic models was improved when MGAT5 expression was added.
  
  
  CONCLUSIONS
  MGAT5 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with ccRCC after nephrectomy.
authors: Key Laboratory of Glycoconjugate Research, MOH, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China.
authors: Yidong
authors: Y
authors: Liu
authors: Key Laboratory of Glycoconjugate Research, MOH, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China.
authors: Haiou
authors: H
authors: Liu
authors: Key Laboratory of Glycoconjugate Research, MOH, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China.
authors: Weisi
authors: W
authors: Liu
authors: Department of Immunology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, 200032, China.
authors: Weijuan
authors: W
authors: Zhang
authors: Department of Urology, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai, 200032, China.
authors: Huimin
authors: H
authors: An
authors: Key Laboratory of Glycoconjugate Research, MOH, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.
authors: Jiejie
authors: J
authors: Xu
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000201:enzymology / Q000235:genetics* / Q000601:surgery; D002681:China / Q000453:epidemiology; D004273:DNA, Neoplasm / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D007680:Kidney Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017350:N-Acetylgalactosaminyltransferases / Q000096:biosynthesis / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D009392:Nephrectomy; D011184:Postoperative Period; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D000097763:Polypeptide N-acetylgalactosaminyltransferase
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D017350:N-Acetylgalactosaminyltransferases; D000097763:Polypeptide N-acetylgalactosaminyltransferase
keywords: Clear-cell renal cell carcinoma; Overall survival; Prognostic biomarker; Recurrence-free survival; β1,6-N-acetylglucosaminyltransferase V
references: Clin Cancer Res. 2000 May;6(5):1772-7
references: 10815896
references: J Biol Chem. 1999 Oct 22;274(43):31039-46
references: 10521503
references: Int J Surg Pathol. 2006 Jan;14(1):65-72
references: 16501837
references: J Clin Oncol. 2008 Jun 1;26(16):2707-16
references: 18509183
references: Clin Cancer Res. 1995 Sep;1(9):935-44
references: 9816064
references: Anticancer Res. 2008 Jul-Aug;28(4A):1993-9
references: 18649738
references: J Biol Chem. 2002 May 10;277(19):16960-7
references: 11864986
references: J Cancer Res Clin Oncol. 1997;123(5):296-9
references: 9201254
references: J Urol. 2009 Oct;182(4):1287-93
references: 19683281
references: JAMA. 1982 May 14;247(18):2543-6
references: 7069920
references: Nat Med. 2000 Mar;6(3):306-12
references: 10700233
references: Glycobiology. 2013 Sep;23(9):1097-109
references: 23811795
references: J Biol Chem. 2012 Dec 14;287(51):42835-45
references: 23139422
references: J Gastroenterol. 2014 Apr;49(4):702-14
references: 23588887
references: Adv Cancer Res. 1989;52:257-331
references: 2662714
references: Bioessays. 1999 May;21(5):412-21
references: 10376012
references: Nature. 2001 Feb 8;409(6821):733-9
references: 11217864
references: Eur Urol. 2007 Jun;51(6):1502-10
references: 17408850
references: Br J Cancer. 2007 Dec 3;97(11):1538-44
references: 17971775
references: Springerplus. 2013 Dec 06;2:657
references: 24349959
references: Eur Urol. 2007 Jun;51(6):1616-24
references: 17207909
references: Clin Cancer Res. 1997 Jul;3(7):1077-86
references: 9815786
references: J Immunol. 2008 Mar 1;180(5):3158-65
references: 18292539
references: Clin Cancer Res. 2006 Apr 15;12(8):2506-11
references: 16638859
references: J Immunol. 2004 Dec 15;173(12):7200-8
references: 15585841
references: J Clin Oncol. 2002 Dec 1;20(23):4559-66
references: 12454113
references: Cancer Res. 1991 Jan 15;51(2):718-23
references: 1985789
references: J Biol Chem. 1982 Nov 25;257(22):13421-7
references: 6216250
references: Cancer Treat Rev. 2008 May;34(3):193-205
references: 18313224
references: Cancer Sci. 2013 Feb;104(2):185-93
references: 23107376
references: Clin Cancer Res. 2004 Mar 1;10(5):1773-9
references: 15014031
references: J Urol. 2002 Dec;168(6):2395-400
references: 12441925
references: J Urol. 2005 Jun;173(6):1853-62
references: 15879764
references: Mol Cancer Ther. 2003 Nov;2(11):1207-14
references: 14617794
references: Cancer Res. 2002 Dec 1;62(23):6837-45
references: 12460896
references: Lancet Oncol. 2013 Jan;14(1):81-7
references: 23219378